Financial Shenanigans

Financial Shenanigans — Senores Pharmaceuticals Ltd

Senores Pharmaceuticals is a rapidly-scaling generic pharma company with a coherent business narrative — USFDA-approved products, growing ANDA portfolio, US CDMO contracts — but its income statement and cash flow statement have parted ways for four consecutive years. The forensic risk score is 42 out of 100 (Elevated): two structural red flags around cash non-conversion and DPO collapse anchor the grade, offset by a genuinely clean revenue story and improving recent-quarter cash trajectories. The single data point that would most change this grade is whether FY2026 full-year operating cash flow turns positive without working-capital tricks.

The Forensic Verdict

13-Shenanigan Scorecard

Breeding Ground

The governance structure at Senores is better than many small-cap pharma IPOs but has three specific weaknesses that amplify accounting risk.

The breeding-ground risk is moderate, not severe. The MD's presence on the Audit Committee is the most structurally concerning item. The small auditor amplifies risk because it cannot credibly challenge the US consolidation. These conditions do not prove manipulation but lower the bar for accounting judgment to drift.

Earnings Quality

Reported earnings are growing fast and appear organic, but the margin profile and one-time income line deserve scrutiny.

Revenue vs Receivables-Proxy Test

In FY2025, "Other Assets" grew 161% while revenue grew 85%. This divergence is the most important balance-sheet warning in this report. "Other Assets" is a catch-all line in Screener's consolidated balance sheet that includes trade receivables, advance tax, prepayments, cash, and intangibles — the company does not disaggregate it in public quarterly disclosures.

Given that DSO improved from 191 to 114 days, the revenue-to-receivable relationship is actually improving. The bulk of the "Other Assets" increase therefore must be in one of: (1) cash and equivalents post-IPO (₹500 Cr raised, ₹137.9 Cr still in FDs at December 2025), (2) advance payments to US API suppliers, (3) ANDA intangibles capitalized, or (4) non-trade advances to subsidiaries. Without disaggregated balance-sheet notes, this cannot be resolved from public disclosures alone.

Margin Consistency

The FY2023 operating margin of 36% was anomalous — revenue was only ₹35 Cr (tiny base with high pricing product mix). The FY2024 compression to 19% reflects the Ratnatris and Havix consolidation bringing in lower-margin businesses. The FY2025 recovery to 23% and TTM 27% is coherent with the regulated market product mix (EBITDA margin ~38% in that segment) accounting for 60% of revenue. This is not a manipulation signal; it reflects product mix improvement.

One-time income flag: FY2025 "Other Income" jumped to ₹19.3 Cr from ₹3.3 Cr in FY2024. Q4 FY2025 alone contributed ₹12 Cr. The company raised ₹500 Cr via IPO in December 2024 and parked proceeds in FDs. At ~9% p.a. for one quarter, ₹500 Cr would generate ~₹11.3 Cr — exactly matching the Q4 spike. This is mechanical and disclosed, not a manipulation. But it will disappear as proceeds are deployed, and the FY2026 Other Income run-rate should fall to under ₹5 Cr.

Capex vs Depreciation: FCF was -₹203 Cr in FY2025, implying capex of approximately ₹157 Cr (CFO -₹46 Cr + capex = -₹203 Cr). Against depreciation of ₹17 Cr, capex/depreciation is ~9x — extremely high, reflecting the CWIP build (Atlanta facility expansion, second API plant). The CWIP drop from ₹172 Cr to ₹16 Cr between March and September 2025 confirms these investments were completed. This is growth capex, not hidden opex, but it explains why FCF will not normalize until capex moderates.

Cash Flow Quality

This is the most important section of this report. The company has never generated positive operating cash flow in four years of reported history, despite reporting positive net income in three of those four years.

CFO vs Net Income — Four Years of Non-Conversion

The three-year (FY2023–FY2025) aggregate CFO is -₹73 Cr against aggregate net income of ₹99 Cr, giving a CFO/NI ratio of -0.74x. Free cash flow (CFO minus capex per the Screener FCF line) over the same period is -₹329 Cr, giving FCF/NI of -3.32x. These are severe metrics for a company trading at 43x earnings.

The accrual ratio in FY2025 is 11.2% ((Net Income - CFO) / Average Total Assets = (58 - (-46)) / 924.5 = 0.112). A positive accrual ratio means the company is reporting more income than it is collecting in cash — earnings are accrual-inflated.

The DPO Collapse — The Structural Driver

Three movements dominate this chart:

DSO improvement (green): DSO fell from 506 days to 114 days. This is genuine and significant. The company is collecting receivables much faster relative to revenue as the US CDMO business grows (predictable cash terms with pharma partners) and the business scales.

DPO collapse (red): Days payable fell from 556 days (FY2024) to 275 days (FY2025) — a compression of 281 days. With COGS approximately ₹309 Cr, this translates to a working capital drain of ~₹237 Cr in a single year just from the payables side. If DPO had stayed at 556 days, FY2025 CFO would have turned approximately break-even. The collapse is the primary reason CFO is -₹46 Cr despite net income of ₹58 Cr.

DIO surge (purple): Inventory days went from 184 to 232 days. In pharma, pre-launch inventory builds ahead of ANDA approvals are normal. With 51 pipeline products and five targeted launches in Q4 FY25, some inventory build is expected. But 232 days of inventory against ₹309 Cr COGS = ₹196 Cr of inventory at year-end. This needs to convert to receivables and cash before it can be trusted.

CCC reversal: Cash Conversion Cycle moved from -182 days to +70 days — a swing of 252 days. The prior two years' negative CCC was working-capital-funded growth; FY2025 marked the end of that artificial tailwind.

The critical forensic question is: why did DPO collapse? The most likely explanation is that Havix (US subsidiary, acquired May 2023) operates on normal US pharma payment terms (net 30–60 days), which is structurally shorter than the Indian subsidiary payment norms that dominated prior years. As Havix became a larger share of consolidated operations, the consolidated DPO mechanically fell. This is a structural shift, not manipulation — but it permanently changes the FCF profile of the business.

Cash Flow Bridge — FY2025

Note: the bridge is approximate given Screener-level data; exact line items are in the annual report. The payables swing alone accounts for most of the CFO deficit.

Positive signal: Management disclosed in the Q2 FY26 earnings call that H1 FY26 CFO was approximately ₹31 Cr (vs ₹9 Cr in H1 FY25). If this improvement reflects DPO stabilisation and inventory normalisation, FY2026 could see the first positive full-year CFO in company history. This would meaningfully reduce the forensic concern.

Metric Hygiene

IPO proceeds deviation is the most forensically significant metric issue. Of the ₹107 Cr committed to Havix sterile injection capacity (as stated in the IPO prospectus), only ₹6.98 Cr had been deployed by December 2025 — twelve months after IPO listing. The balance (₹100 Cr) remained as fixed deposits. Separately, ₹128.5 Cr of the ₹154.76 Cr earmarked for "inorganic growth and general corporate purposes" was deployed — used for ANDA portfolio acquisitions and the Apnar Pharma deal (₹91 Cr EV). SEBI Listing Regulations require a "deviation report" if IPO proceed use deviates materially from prospectus disclosure. No such deviation report has been filed as of the data available.

What to Underwrite Next

The forensic risk is real but manageable if the cash conversion trajectory continues improving. Here are the five highest-value items to monitor in the next report cycle.

The bottom line for position sizing: The accounting risk at Senores is a valuation haircut and a position-sizing limiter, not yet a thesis breaker. The revenue story is verifiable — ANDA approvals are public records, USFDA inspections without Form 483 are factual, CDMO contracts with large pharma are named. But the company is priced at 43x earnings on a business that has never converted earnings to cash. The two red flags — persistently negative CFO and the DPO collapse that drove CCC from -182 to +70 days — require a 20–30% discount to any DCF-based valuation until at least two consecutive years of positive operating cash flow are demonstrated. The governance weakness (small auditor, MD on audit committee) and the IPO proceeds deviation lower confidence further. A fund underwriting a new position should require FCF positive evidence before sizing beyond a monitoring stake.